Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2311381 | 0.82 | — | — | |
| SCHEMBL554571 | 0.68 | — | — | |
| SCHEMBL191345 | 0.66 | ALDH1A1 (0.30) | — | |
| SCHEMBL9959990 | 0.64 | — | — | |
| SCHEMBL528426 | 0.64 | PADI4 (0.31) | — | |
| SCHEMBL17766689 | 0.64 | — | — | |
| SCHEMBL17784199 | 0.63 | — | — | |
| SCHEMBL14117987 | 0.63 | TGM2 (0.33) | TGM2 | |
| SCHEMBL17583240 | 0.63 | KDM4E (0.32) | — | |
| SCHEMBL4515373 | 0.60 | ALDH1A1 (0.32) | TGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295713-A1 | COMPOSITIONS AND METHODS FOR IMPROVING SKIN HEALTH AND FOR THE TREATMENT AND PREVENTION OF DISEASES, DISORDERS AND CONDITIONS ASSOCIATED WITH PATHOGENIC MICROBES | DERMBIONT, INC. | 2025-09-25 | — | — | US | disclosed |
| US-12064459-B2 | Compositions and methods for improving skin health and for the treatment and prevention of diseases, disorders and conditions associated with pathogenic microbes | DERMBIONT, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| US-8207321-B2 | Method of obtaining idolocarbazoles using biosynthetic rebeccamycin genes | UNIVERSIDAD DE OVIEDO (ES) | 2012-06-26 | — | — | US | disclosed |
| EP-1443113-B1 | METHOD OF OBTAINING INDOLOCARBAZOLES USING BIOSYNTHETIC REBECCAMYCIN GENES | UNIV OVIEDO (ES) | 2010-08-18 | — | — | EP | disclosed |
| EP-1432721-A4 | PROCESS FOR THE PREPARATION OF REBECCAMYCIN AND ANALOGS THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2008-02-20 | — | — | EP | disclosed |
| US-20080004326-A1 | Method of Obtaining Idolocarbazoles Using Biosynthetic Rebeccamycin Genes | UNIVERSIDAD DE OVIEDO (ES) | 2008-01-03 | — | — | US | disclosed |
| US-20070249590-A1 | Substituted indolo[2,3-a]pyrrolo[3,4-c]carbazole compounds useful in treating kinase disorders | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249590-A1 | Substituted indolo[2,3-a]pyrrolo[3,4-c]carbazole compounds useful in treating kinase disorders | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249590-A1 | Substituted indolo[2,3-a]pyrrolo[3,4-c]carbazole compounds useful in treating kinase disorders | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-25 | — | — | US | disclosed |
| US-7227019-B2 | Process for the preparation of rebeccamycin and analogs thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-05 | — | — | US | disclosed |
| US-20040248892-A1 | Process for the preparation of rebeccamycin and analogs thereof | BRISTOL-MYERS SQUIBB COMPANY | 2004-12-09 | — | — | US | disclosed |
| EP-1443113-A1 | METHOD OF OBTAINING INDOLOCARBAZOLES USING BIOSYNTHETIC REBECCAMYCIN GENES | Universidad De Oviedo (ES) | 2004-08-04 | — | — | EP | disclosed |
| EP-1432721-A1 | PROCESS FOR THE PREPARATION OF REBECCAMYCIN AND ANALOGS THEREOF | Bristol-Myers Squibb Company (US) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003033706-A1 | METHOD OF OBTAINING INDOLOCARBAZOLES USING BIOSYNTHETIC REBECCAMYCIN GENES | UNIVERSIDAD DE OVIEDO (ES) | 2003-04-24 | — | — | WO | disclosed |
| WO-2003022861-A1 | PROCESS FOR THE PREPARATION OF REBECCAMYCIN AND ANALOGS THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249590-A1 | Substituted indolo[2,3-a]pyrrolo[3,4-c]carbazole compounds useful in treating kinase disorders | PRKACA, PRKDC, PACSIN2 | TGM2 2824/4885 |
| US-20040248892-A1 | Process for the preparation of rebeccamycin and analogs thereof | COX4I1, CYC1, CYP11B2 | TGM2 1695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.